Highlights Cutia Therapeutics

Equities

2487

KYG2606C1006

Market Closed - Hong Kong S.E. Other stock markets 09:08:12 14/06/2024 BST			5-day change	1st Jan Change
6.13 ^HKD	-0.16%		-7.12%	-44.17%

06-11	Certain Ordinary Shares of Cutia Therapeutics are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	CI
05-31	Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress	05-31	MT
Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug	05-30	MT
Cutia Therapeutics Announces Investigational New Drug Application of CU-10101 for Atopic Dermatitis Approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China	05-30	CI
Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6%	04-30	MT
Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC	04-29	CI
Cutia Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration	03-26	CI
Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401	02-27	CI
Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration	01-30	CI
Cutia Therapeutics Announces First Patient Enrollment in the Phase II Clinical Trial of CU-20401	01-02	CI
Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China	12-10	CI
Cutia Therapeutics Announces Phase I Clinical Trial of Cu-20401 Abdominal Adipose Accumulation Completes Database Lock	11-27	CI
Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) in China Reached Primary Endpoint	11-02	CI
Cutia Therapeutics Announces All Enrolled Patients Completes Phase I Clinical Trial of CU-20401	24/10/23	CI
Cutia Therapeutics Announces New Drug Application for CU-10201 (Topical 4% Minocycline Foam) Accepted by the National Medical Products Administration	26/09/23	CI
Cutia Therapeutics Announces Registrational Phase III Clinical Trial of the Group's CU-40102 Conducted in China for the Treatment of Androgenetic Alopecia Reached Primary Endpoint	07/09/23	CI
Cutia Therapeutics' H1 Attributable Loss Widens on Surge in Fair Value Losses	29/08/23	MT
Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) Completed Database Lock	28/08/23	CI
Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) Completed Database Lock	28/08/23	CI
Cutia Therapeutics Completes Phase Iii Clinical Trial of Cu-30101	23/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cutia Therapeutics

Equities

2487

KYG2606C1006

Highlights

Filters